A draft evidence report from Boston, USA-based watchdog The Institute for Clinical and Economic Review (ICER) suggests a cost-effective price of up to $1.9 mill 13 April 2023
The progress quietly made by Sino-American biotech company Beigene (Nasdaq: BGNE) with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) 30 March 2023
A short delay to bluebird bio’s US regulatory submission for lovo-cel (lovotibeglogene autotemcel) appears to have spooked investors, with shares in the company 30 March 2023
US biopharma Inozyme Pharma has announced that founding chief executive officer Axel Bolte will retire from his current role, to be replaced by Douglas Treco. 24 March 2023
Patient advocacy groups have expressed regret at Janssen’s decision to hit the pause button on its UK launch of Carvykti (ciltacabtagene autoleucel). 20 March 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.